X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (892) 892
humans (799) 799
oncology (651) 651
1st-line treatment (648) 648
female (496) 496
chemotherapy (434) 434
cancer (327) 327
breast cancer (315) 315
open-label (260) 260
middle aged (257) 257
metastasis (255) 255
treatment outcome (255) 255
aged (244) 244
care and treatment (243) 243
adult (231) 231
breast neoplasms - drug therapy (229) 229
antineoplastic combined chemotherapy protocols - therapeutic use (221) 221
male (211) 211
1st-line therapy (187) 187
bevacizumab (180) 180
pharmacology & pharmacy (176) 176
drug therapy (168) 168
double-blind (166) 166
phase-iii trial (162) 162
health aspects (161) 161
antineoplastic agents - therapeutic use (160) 160
research (155) 155
breast neoplasms - pathology (151) 151
phase-ii trial (151) 151
clinical trials (144) 144
colorectal cancer (139) 139
medicine & public health (133) 133
cancer therapies (129) 129
neoplasm metastasis (129) 129
hematology, oncology and palliative medicine (128) 128
analysis (124) 124
gastroenterology & hepatology (120) 120
disease-free survival (113) 113
therapy (112) 112
helicobacter pylori (108) 108
capecitabine (105) 105
colorectal neoplasms - drug therapy (105) 105
antineoplastic combined chemotherapy protocols - adverse effects (104) 104
survival (104) 104
trastuzumab (103) 103
animals (102) 102
review (102) 102
mutation (101) 101
combination (100) 100
patients (99) 99
tumors (99) 99
endothelial growth-factor (97) 97
metastatic breast cancer (96) 96
paclitaxel (96) 96
prognosis (95) 95
1st-line chemotherapy (93) 93
trial (93) 93
drug therapy, combination (92) 92
helicobacter infections - drug therapy (89) 89
cell lung-cancer (88) 88
docetaxel (88) 88
oxaliplatin (87) 87
development and progression (85) 85
randomized-trial (85) 85
vascular endothelial growth factor (84) 84
infection (82) 82
efficacy (81) 81
phase-iii (81) 81
clinical trials as topic (80) 80
colorectal neoplasms - pathology (80) 80
lung neoplasms - drug therapy (78) 78
angiogenesis (77) 77
growth-factor receptor (77) 77
aged, 80 and over (76) 76
fluorouracil (76) 76
antineoplastic agents (75) 75
breast neoplasms - metabolism (74) 74
neoplasm staging (74) 74
carcinoma, non-small-cell lung - drug therapy (73) 73
angiogenesis inhibitors - therapeutic use (71) 71
antimitotic agents (71) 71
biomarkers (71) 71
clarithromycin (69) 69
deoxycytidine - analogs & derivatives (69) 69
phase-ii (69) 69
tyrosine kinase inhibitor (69) 69
lung cancer (68) 68
resistance (67) 67
drug resistance (64) 64
molecular targeted therapy (64) 64
antineoplastic combined chemotherapy protocols - administration & dosage (63) 63
drug administration schedule (63) 63
metastases (63) 63
neoadjuvant chemotherapy (63) 63
cetuximab (62) 62
epidermal growth factor (62) 62
fluorouracil - administration & dosage (62) 62
irinotecan (62) 62
randomized controlled trials as topic (62) 62
medical research (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1075) 1075
German (4) 4
French (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 05/2018, Volume 24, Issue 5, pp. 628 - 637
Journal Article
INTERNATIONAL JOURNAL OF CANCER, ISSN 0020-7136, 10/2014, Volume 135, Issue 8, pp. 1961 - 1969
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial... 
VEGFR2 | 1ST-LINE TREATMENT | apatinib | TYROSINE KINASE | OPEN-LABEL | TUMOR ANGIOGENESIS | SUNITINIB PLUS PACLITAXEL | RENAL-CELL CARCINOMA | TRIAL | ONCOLOGY | metastatic breast cancer | IN-VIVO | triple negative | DOUBLE-BLIND | EXPRESSION
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 04/2019, Volume 34, Issue 4, pp. 686 - 692
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 03/2016, Volume 111, Issue 3, pp. 381 - 387
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2015, Volume 41, Issue 6, pp. 581 - 589
Journal Article
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 12/2013, Volume 28, Issue 12, pp. 1801 - 1809
Journal Article
Breast, The, ISSN 0960-9776, 2013, Volume 22, Issue 5, pp. 650 - 656
Abstract Purpose This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC)... 
Hematology, Oncology and Palliative Medicine | Sunitinib | Phase II | Standard-of-care chemotherapy | Receptor tyrosine kinases | Triple-negative breast cancer | 1ST-LINE TREATMENT | METASTASIS | ANGIOGENESIS | TUMORS | RENAL-CELL CARCINOMA | SU11248 | OBSTETRICS & GYNECOLOGY | TRIAL | ONCOLOGY | KIT | TYROSINE KINASE INHIBITOR | GROWTH-FACTOR | Pyrroles - pharmacokinetics | Capecitabine | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Hand-Foot Syndrome - etiology | Triple Negative Breast Neoplasms - drug therapy | Fluorouracil - therapeutic use | Taxoids - therapeutic use | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Triple Negative Breast Neoplasms - pathology | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Chemotherapy, Adjuvant | Neutropenia - chemically induced | Pyrroles - therapeutic use | Fluorouracil - analogs & derivatives | Survival Rate | Thrombocytopenia - chemically induced | Paclitaxel - therapeutic use | Disease-Free Survival | Indoles - adverse effects | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Anthracyclines - therapeutic use | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical research | Care and treatment | Chemotherapy | Clinical trials | Medicine, Experimental | Breast cancer | Antineoplastic agents | Patients | Standards | Cancer | Index Medicus
Journal Article
Digestive and Liver Disease, ISSN 1590-8658, 2014, Volume 47, Issue 2, pp. 108 - 113
Journal Article
Helicobacter, ISSN 1083-4389, 06/2018, Volume 23, Issue 3, pp. e12485 - n/a
BackgroundHelicobacter pylori (H. pylori) eradication has become increasingly difficult especially for penicillin allergy patients. AimsTo evaluate the... 
allergy | high dose of metronidazole | Helicobacter pylori | bismuth | LANSOPRAZOLE | ANTIBIOTIC-RESISTANCE | OMEPRAZOLE | MICROBIOLOGY | AMOXICILLIN | TRIAL | QUADRUPLE THERAPY | ERADICATION | INFECTION | 1ST-LINE | GASTROENTEROLOGY & HEPATOLOGY | PENICILLIN | Bismuth - administration & dosage | Esomeprazole - administration & dosage | Humans | Middle Aged | Drug Resistance, Bacterial | Esomeprazole - adverse effects | Male | Bismuth - adverse effects | Microbial Sensitivity Tests | Proton Pump Inhibitors - administration & dosage | China | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Adult | Female | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Drug Therapy, Combination | Proton Pump Inhibitors - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Breath Tests | Treatment Outcome | Aged | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Allergy | Medical research | Urea | Drug resistance in microorganisms | Clarithromycin | Medicine, Experimental | Bismuth | Allergic reaction | Therapy | Hypersensitivity | Antimicrobial agents | Patients | Antiinfectives and antibacterials | Omeprazole | Dilution | Randomization | Inhibitors | Motivation | Penicillin | Extracellular matrix | Metronidazole | Antimicrobial resistance | Index Medicus
Journal Article